About Corbus Pharmaceuticals Holdings Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.corbuspharma.com/
Frequently Asked Questions
What is the 52-week range for CRBP?
The 52-week high is $20.56 and the 52-week low is $6.06.
What is the P/E ratio for CRBP?
The P/E ratio data is currently unavailable.
What is the dividend yield for CRBP?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -87.05%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -2838.71%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.97.
Analyst Recommendation Trends
Wall Street analyst consensus for CRBP over the last few months:
Latest CRBP News
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infection OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with approximately 14,000 patients eligible for treatment annually NORWOOD, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that the first patient has been dosed in i
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy - Slideshow
2026-09-17. The following slide deck was published by Corbus Pharmaceuticals Holdings, Inc.
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?
Corbus Pharmaceuticals' positive obesity data boosts its cannabinoid strategy, while CRB-701 and cash needs add key context for investors.
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study
Corbus Pharmaceuticals (NASDAQ:CRBP) reported top-line results from CANYON-1, a Phase 1b trial evaluating CRB-913, an oral, peripherally restricted CB1 inverse agonist for obesity. The 12-week, placebo-controlled study enrolled 254 patients across 15 U.S. sites, with participants having an average b
Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) shares rose 12% on Monday after the company reported topline results from its CANYON-1 Phase 1b clinical trial evaluating CRB-913 as a treatment for obesity.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy Transcript
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy September 14, 2026 8:00 AM...
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $35 price target.
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observedCRB-913 was generally well tolerated with psychiatric adverse events broadly in line with GLP-1 drugs and a favorable emerging GI tolerability profile Data support CRB-913’s potential to establish a new class of oral non-incretin obesity medicinesData selected for late-breaking presentation at ObesityWeek® 2026Company will hold an investor call at 8:00am
Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'
Corbus Pharmaceuticals reports positive Phase 1b trial results for obesity drug CRB-913, demonstrating significant 12-week weight loss.
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics (NASDAQ:DFTX)
Market-Moving News for September 14th
GLW: -8% | Corning shares are trading lower after the company announced a $2 billion offering. ELMT: 49% | Elmet Group Lands $450M US Government Investment To Expand Tungsten Manufacturing, To Invest More Than $165M
Corbus Pharma Announces Topline Data From CANYON-1 Phase 1b Trial Of CRB-913 Demonstrating Statistically Significant And Clinically Meaningful Weight Loss In Obesity
CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric adverse events
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
Wondering what's happening in today's after-hours session?
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDTNORWOOD, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today announced that the Company’s management team will host a conference call webcast on Monday, September 14 at 8:00 a.m. EDT, to discuss topline data for CANYON-1, a Phase 1b study of CRB-913 for the treatment of obesity. Harold Bays, M.
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
Corbus Pharmaceuticals To Report Topline CANYON-1 Obesity Trial Data For CRB-913; Management Team Will Host A Conference Call Webcast On Monday, September 14 At 8:00 a.m. EDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today announced that the Company’s management team will host a conference call
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-14 | Ben Yong | -2,000 | $7.8415 | $15,683 |
| 2026-08-16 | Nicacio Leonardo Viana | +191,676 | - | - |
| 2026-08-16 | Nicacio Leonardo Viana | +58,333 | - | - |
| 2026-08-11 | Saxena Nishant C | +2,600 | $9.6294 | $25,036 |
| 2026-08-07 | Cohen Yuval | -17,000 | $10.0821 | $171,396 |
| 2026-08-07 | Moran Sean F. | -12,000 | $10.0809 | $120,971 |
| 2026-06-10 | Kung Winston | -2,026 | $7.9137 | $16,033 |
| 2026-06-10 | Jenkins John Kenneth | -4,800 | $7.9137 | $37,986 |
| 2026-06-10 | Altmeyer Anne | -2,412 | $7.9137 | $19,088 |
| 2026-06-03 | Saxena Nishant C | +9,000 | $7.58 | $68,220 |
| 2026-06-02 | Saxena Nishant C | +4,500 | $7.333 | $32,999 |
| 2026-05-21 | Saxena Nishant C | +192,300 | - | - |
| 2026-05-21 | Saxena Nishant C | +58,300 | - | - |
| 2026-05-19 | Kung Winston | +12,300 | - | - |
| 2026-05-19 | Kung Winston | +3,800 | - | - |
| 2026-05-19 | Jacques Rachelle Suzanne | +12,300 | - | - |
| 2026-05-19 | Jacques Rachelle Suzanne | +3,800 | - | - |
| 2026-05-19 | Jenkins John Kenneth | +12,300 | - | - |
| 2026-05-19 | Jenkins John Kenneth | +3,800 | - | - |
| 2026-05-19 | Altmeyer Anne | +12,300 | - | - |
| 2026-05-19 | Altmeyer Anne | +3,800 | - | - |
| 2026-05-19 | Ben Yong | +12,300 | - | - |
| 2026-05-19 | Ben Yong | +3,800 | - | - |
| 2026-05-19 | Pfeiffenberger Brent | +24,700 | - | - |
| 2026-05-19 | Pfeiffenberger Brent | +7,500 | - | - |
| 2026-03-02 | Smethurst Dominic | -6,097 | $8.2994 | $50,601 |
| 2026-02-17 | Hodgson Ian | -847 | $7.383 | $6,253 |
| 2026-02-13 | Cohen Yuval | -13,871 | $7.7826 | $107,952 |
| 2026-02-13 | Moran Sean F. | -4,701 | $7.783 | $36,588 |
| 2026-02-03 | Smethurst Dominic | -3,285 | $8.0898 | $26,575 |
| 2026-02-03 | Hodgson Ian | -2,415 | $8.0899 | $19,537 |
| 2026-01-14 | Hodgson Ian | +85,095 | - | - |
| 2026-01-14 | Hodgson Ian | +28,365 | - | - |
| 2026-01-14 | Smethurst Dominic | +85,095 | - | - |
| 2026-01-14 | Smethurst Dominic | +28,365 | - | - |
| 2026-01-14 | Cohen Yuval | +150,000 | - | - |
| 2026-01-14 | Cohen Yuval | +50,000 | - | - |
| 2026-01-14 | Moran Sean F. | +84,247 | - | - |
| 2026-01-14 | Moran Sean F. | +28,082 | - | - |
| 2025-12-11 | Cormorant Asset Management, LP | -30,029 | $11.456 | $344,012 |
| 2025-10-27 | Cohen Yuval | -8,973 | - | - |
| 2025-10-27 | Cohen Yuval | -8,973 | $17.14 | $153,797 |
| 2025-10-27 | Cohen Yuval | +8,973 | $4.26 | $38,225 |
| 2025-10-24 | Cohen Yuval | -18,660 | - | - |
| 2025-10-24 | Cohen Yuval | -18,660 | $17.01 | $317,407 |
| 2025-10-24 | Cohen Yuval | +18,660 | $4.26 | $79,492 |
| 2025-10-24 | Moran Sean F. | -12,981 | - | - |
| 2025-10-24 | Moran Sean F. | -12,981 | $17.02 | $220,937 |
| 2025-10-24 | Moran Sean F. | +12,981 | $4.26 | $55,299 |
| 2025-10-20 | Altmeyer Anne | -1,060 | - | - |
| 2025-10-20 | Altmeyer Anne | -1,060 | $20.5 | $21,730 |
| 2025-10-20 | Altmeyer Anne | +1,060 | $4.8 | $5,088 |